The US Food and Drug Administration (FDA) has approved Lembaz (adrabetadex) for the treatment of infantile-Niemann Pick disease type C (NPC).
NPC is a complex lysosomal storage disorder mainly characterized by the accumulation of unesterified cholesterol in lysosomes. Symptoms may include lack of muscle coordination, brain degeneration, learning problems, loss of muscle tone, increased sensitivity to touch, spasticity, feeding and swallowing difficulties, slurred speech, and an enlarged liver and spleen.
Adrabetadex is the first FDA approved medicine to address the underlying cholesterol trafficking defect that causes NPC. The treatment is designed to target the cholesterol that builds up inside neurons by replacing the function of the NPC protein that is not working properly and helping move cholesterol to where the cell can use it. Adrabetadex is approved for adults and children with NPC who had neurological manifestations that started before the age of 6.
The efficacy of adrabetadex was based on an overall survival analysis in people with infantile NPC across three clinical studies and an Expanded Access Program, compared with matched external controls. The analysis showed a 55%reduction in the risk of mortality.
Alongside the treatment approval, Beren has launched two initiatives to support families: LEMBAZ Family Support, offering comprehensive financial assistance and personalized support, and the Caregiver Ambassador Program, to connect families considering LEMBAZ with caregivers who have firsthand experience with treatment.
The company also received a Priority Review Voucher upon this approval since the orphan drug has a pediatric indication.
For more information, visit https://www.businesswire.com/LEMBAZ
To learn more about NPC and other are metabolic conditions, visit https://checkrare.com/diseases/metabolic-disorders/
